Current Trials
Ongoing Trials
Anifrolumab (NCT05138133) - Lupus Nephritis
Sponsor: AstraZeneca
Phase: 3
Accrual Status: Recruiting
Rayulizumab (NCT04564339) - Lupus Nephritis
Sponsor: Alexion Pharmaceuticals, Inc.
Phase: 2
Accrual Status: Active, not recruiting
Rayulizumab (NCT06291376) - IgA Nephropathy
Sponsor: Alexion Pharmaceuticals, Inc.
Phase: 3
Accrual Status: Recruiting
Atacicept (NCT04716231) - IgA Nephropathy
Sponsor: Vera Therapeutics, Inc.
Phase: 3
Accrual Status: Recruiting
Sefaxersen (NCT05797610) - IgA Nephropathy
Sponsor: Hoffman-La Roche
Phase 3:
Accrual Status: Pending open to accrual
Iptacopan (NCT04578834) - IgA Nephropathy
Sponsor: Novartis Pharmaceuticals
Phase: 3
Accrual Status: Active, not recruiting
DISC-0974 (NCT05745883) - CKD
Sponsor: Disc Medicine, Inc.
Phase: 1b
Accrual Status: Recruiting
Finerenone (NCT05047263) - CKD
Sponsor: Bayer
Phase: 3
Accrual Status: Active, not recruiting
Vonafexor (NCT06425055) - Alport Syndrome
Sponsor: Enyo Pharma
Phase: Proof-of-concept study
Accrual Status: Active, not recruiting
Prismocitrate 18 (NCT05399537) - Renal Replacement Therapy
Sponsor: Baxter
Phase: 3
Accrual Status: Pending open to accrual
Observational Program (NCT00196742) - Fabry
Sponsor: Genzyme, a Sanofi company
Phase: Registry
Accrual Status: Recruiting
HM15421/GC1134A - Fabry
Sponsor: Hanmi Pharmaceutical Co. LTF., GC Biopharma Corp
Phase 1/2
Accrual Status: Pending open to accrual
Venglustat (NCT05280548) - Fabry
Sponsor: Sanofi
Phase: 3
Accrual Status: Active, not recruiting
FabrazymE (NCT06019728) - Fabry
Sponsor: Sanofi
Phase: 4
Accrual Status: Active, not recruiting
Venglustat (NCT05206773) - Fabry
Sponsor: Sanofi
Phase: 3
Accrual Status: Active, not recruiting
Repagermanium (NCT05183646) - FSGS
Sponsor: Dimerix Bioscience Pty Ltd
Phase: 3
Accrual Status: Pending open to accrual
ABBV-CLS-628 - ADPKD
Sponsor: Abbvie
Phase: 2
Accrual Status: Pending open to accrual